These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1288660)

  • 1. The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes.
    Reid WG
    Int Psychogeriatr; 1992; 4 Suppl 2():147-60. PubMed ID: 1288660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).
    Reid WG; Hely MA; Morris JG; Loy C; Halliday GM
    J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):1033-7. PubMed ID: 21335570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical observations in early and late onset Parkinson's disease.
    Bostantjopoulou S; Logothetis J; Katsarou Z; Mentenopoulos G
    Funct Neurol; 1991; 6(2):145-9. PubMed ID: 1916456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.
    Montastruc JL; Celsis P; Agniel A; Demonet JF; Doyon B; Puel M; Marc-Vergnes JP; Rascol A
    Mov Disord; 1987; 2(4):279-89. PubMed ID: 3509776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-onset Parkinson's disease.
    Giovannini P; Piccolo I; Genitrini S; Soliveri P; Girotti F; Geminiani G; Scigliano G; Caraceni T
    Mov Disord; 1991; 6(1):36-42. PubMed ID: 2005920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memory and executive function impairment predict dementia in Parkinson's disease.
    Levy G; Jacobs DM; Tang MX; Côté LJ; Louis ED; Alfaro B; Mejia H; Stern Y; Marder K
    Mov Disord; 2002 Nov; 17(6):1221-6. PubMed ID: 12465060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method of addition of bromocriptine to the drug regime of patients with advanced Parkinson's disease.
    Grimes JD; Hassan MN
    Can J Neurol Sci; 1981 Feb; 8(1):31-4. PubMed ID: 7225954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG.
    Zhu K; van Hilten JJ; Marinus J
    Parkinsonism Relat Disord; 2014 Sep; 20(9):980-5. PubMed ID: 25024059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study.
    Riedel O; Heuser I; Klotsche J; Dodel R; Wittchen HU;
    J Geriatr Psychiatry Neurol; 2010 Mar; 23(1):27-34. PubMed ID: 20042544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease.
    Giladi N; Treves TA; Paleacu D; Shabtai H; Orlov Y; Kandinov B; Simon ES; Korczyn AD
    J Neural Transm (Vienna); 2000; 107(1):59-71. PubMed ID: 10809404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
    Sternić N; Kostić V
    Srp Arh Celok Lek; 1992; 120(1-2):1-5. PubMed ID: 1641693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairments in different stages of Parkinson's disease.
    Starkstein SE; Bolduc PL; Preziosi TJ; Robinson RG
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):243-8. PubMed ID: 2521068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled study of dementia in Parkinson's disease over 54 months.
    Mindham RH; Biggins CA; Boyd JL; Harrop FM; Madeley P; Randall JI; Spokes EG
    Adv Neurol; 1993; 60():470-4. PubMed ID: 8420172
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.